Premium
Parenteral antischistosomal therapy: A potential risk factor for hepatitis B infection
Author(s) -
Hyams Kenneth C.,
Mansour Moustafa M.,
Massoud Ahmed,
Dunn Michael A.
Publication year - 1987
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890230203
Subject(s) - schistosomiasis , hbsag , medicine , hepatosplenomegaly , schistosoma mansoni , risk factor , immunology , hepatitis b , virology , hepatitis , hepatitis b virus , gastroenterology , virus , disease , helminths
To study the association between hepatitis B and schistosomiasis, 1,234 Egyptian males, ages 18 to 24, were interviewed, examined, and tested for Schistosoma mansoni infection and HBsAg. Sera from 91 (7.4%) of the study subjects were positive for HBsAg, and S. mansoni was found in the stools of 26.3%. There was no correlation between S. mansoni infection, with or without hepatosplenomegaly, or a history of schistosomiasis, and HBsAg. An association was found between HBsAg positivity and a previous history of parenteral antischistosomal therapy (P < 0.01). The results of the study indicate that parenteral therapy for schistosomiasis may be a risk factor for hepatitis B antigenemia. Further studies are indicated to determine the importance of parenteral therapy in the transmission of hepatitis B.